• metastatic/adv melanoma (mML)
• mML - (neo)adjuvant (NA)
• mML - NA - all population 9
• mML - NA - PDL1 positive 1
• mML - 1st line (L1)
• mML - L1 - all population 7
• mML - L1 - BRAF mutant 2
• mML - L1 - BRAF wild 3
• mML - 2nd line (L2)
• mML - L2 - all population 11
• mML - L2 - BRAF mutant 1
• mesothelioma (MS)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• Ipilimumab (10 mg/kg)
• ipilimumab plus gp100
• ipilimumab plus SoC
• tremelimumab
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus cometinib
• atezolizumab plus SoC
• nivolumab based treatment
• nivolumab alone
• nivolumab followed by ipilimumab
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (10mg/kg) 2 weeks
• pembrolizumab (2mg/kg)
• pembrolizumab plus SoC
• Immune checkpoint association
• nivolumab plus ipilimumab
• relatlimab plus nivolumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs alkylating agents
• vs dacarbazine
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs ipilimumab based treatment
• vs ipilimumab alone
• vs Ipilimumab (10 mg/kg)
• vs ipilimumab followed by nivolumab
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs pembrolizumab based treatment
• vs pembrolizumab alone
• vs Immunostimulant
• vs interferon alpha
• vs vaccine
• vs gp100
• vs non active control
• vs placebo

  All patients Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

metastatic/adv melanoma (mML), anti-CTLA-4 vs. Standard of Care (SoC), meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;